Post Procedure Anticoagulation Medication Strategies and Variations - 2020 Quality Summit presentation (Non-CE)-Post Procedure Anticoagulation Medication Strategies and Variations

Post Procedure Anticoagulation Medication Strategies and Variations - Varosy

Video Transcription

Video Summary

Dr. Paul Verossi presents on post-procedure anticoagulation medication strategies and variations in the LAO Registry. He discusses the background, challenges, and controversies surrounding the management of patients undergoing left atrial appendage occlusion for non-valvular atrial fibrillation. Dr. Verossi explains the use of oral anticoagulants, the emergence of direct oral anticoagulants (DOACs), and the conflicts between DOAC therapy and the FDA-approved drug regimen using warfarin. He also highlights the challenges of managing patients at high risk of both stroke and bleeding. Dr. Verossi mentions the use of the Watchman device for left atrial appendage occlusion as an alternative to oral anticoagulation and the evolving evidence around DOACs and their use in combination with left atrial appendage occlusion. He emphasizes the need for more data and the role of the NCDR left atrial appendage occlusion registry in capturing and understanding the evolving practices and outcomes in real-world practice. The video concludes with a Q&A session, addressing questions about medication regimens, the use of P2Y12 inhibitors, the role of the registry in capturing adverse events, and the impact of CHADS-VASc risk scores on procedural outcomes.

Keywords

anticoagulation medication

LAO Registry

left atrial appendage occlusion

DOAC therapy

warfarin

stroke

bleeding

Watchman device